复发/转移性头颈部鳞癌的免疫治疗现状和未来

Immunotherapy of recurrent/metastatic head and neck squamous cell carcinoma: recent achievements and future directions

临床上,复发/转移性头颈部鳞癌的标准治疗方式依赖于以铂类为基础的化疗联合西妥昔单抗,然而患者中位生存期仅6~10个月。因此,提高复发/转移性头颈部鳞癌的疗效是一个亟需解决的问题。近年来,以PD-1/PD-L1为代表的免疫检查点抑制剂的出现为不可治愈的复发/转移性头颈部鳞癌患者的治疗提供了新的选择。各种免疫治疗与化疗、靶向治疗的联合疗法、过继性细胞治疗等免疫疗法逐渐成为未来肿瘤治疗的发展方向。本文就复发/转移性头颈部鳞癌最新的免疫治疗临床研究进展予以评述,并对潜在的免疫治疗生物标记物进行阐述。

The current treatment of recurrent/metastatic head and neck squamous cell cancer(R/M HNSCC)relies on platinum-based chemotherapy combined with cetuximab.But patients’median overall survival is restricted to 6-10 months.Recently,the emergence of immune checkpoint inhibitors represented by PD-1/PD-L1 has provided new treatment options for patients with incurable R/M HNSCC.Immunotherapy combined with chemotherapy,targeted therapy,adoptive cell therapy and other immunotherapies have become widely available.Here,we reviewed the recent achievements and discussed future directions in the immunotherapy for R/M HNSCC.Potential biomarkers for immunotherapy were also examined.